Genedrive PLC Result of AGM (9013U)

TIDMGDR

RNS Number : 9013U

Genedrive PLC

27 November 2019

genedrive plc

("genedrive" or the "Company")

Result of AGM

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

For information, details of the proxy voting are shown below:

 
  Resolution                   Votes For      Votes For      Votes   Votes Against   Votes Withheld 
                                               (as % of    Against        (as % of 
                                            votes cast)                votes cast) 
 1. Receive the Annual 
  report and accounts 
  for the Company             22,673,789         100.0%          0           0.00%              515 
                             -----------  -------------  ---------  --------------  --------------- 
 2. Approve the Directors' 
  Remuneration Report         21,886,545          96.5%    787,131           3.47%              628 
                             -----------  -------------  ---------  --------------  --------------- 
 3. Re-appoint Tom 
  Lindsay as a director       22,674,304         100.0%          0           0.00%                0 
                             -----------  -------------  ---------  --------------  --------------- 
 4. Re-appoint Chris 
  Yates as a director         22,674,304         100.0%          0           0.00%                0 
                             -----------  -------------  ---------  --------------  --------------- 
 5. Re-appoint David 
  Budd as a director          22,674,304         100.0%          0           0.00%                0 
                             -----------  -------------  ---------  --------------  --------------- 
 6. Re-appoint Matthew 
  Fowler as a director        22,674,304         100.0%          0           0.00%                0 
                             -----------  -------------  ---------  --------------  --------------- 
 7. Re-appoint Ian 
  Gilham as a director        21,887,370         100.0%        314           0.00%          786,620 
                             -----------  -------------  ---------  --------------  --------------- 
 8. Appoint RSM UK 
  as auditors of the 
  Company                     22,674,304         100.0%          0           0.00%                0 
                             -----------  -------------  ---------  --------------  --------------- 
 9. Directors' authority 
  to allot shares             22,109,087         100.0%          0           0.00%          565,217 
                             -----------  -------------  ---------  --------------  --------------- 
 10. Disapplication 
  of pre-emption rights       19,551,681          88.4%  2,556,891          11.57%          565,732 
                             -----------  -------------  ---------  --------------  --------------- 
 

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com).

- Ends -

For further details please contact:

 
 genedrive plc                                                    www.genedriveplc.com 
 David Budd: CEO / Matthew Fowler: 
  CFO                                                              [phone] 
 
 
 Peel Hunt LLP                                                     [phone] 
 James Steel / Oliver Jackson 
 
 Stanford Capital Partners Limited                                 [phone] 
 Patrick Claridge / John Howes 
 
 Walbrook PR Ltd (Media Relations &    [phone] or [e-mail] 
  Investor Relations) 
                                                     [phone] / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                    741 001 
 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGBLBDBGDDBGCR

(END) Dow Jones Newswires

November 27, 2019 11:23 ET (16:23 GMT)